ArticleClinical, cosmetic and investigational dermatology2025
Evaluation of the Effect of Patient-Initiated Antiviral Therapy on the Frequency of the Recurrent Herpes Simplex Viral Infection: A Single Center, Retrospective Study.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Although recurrent herpes simplex (RHS) is usually self-limiting, it can significantly impair quality of life due to frequent recurrences and associated symptoms. Patient-initiated therapy (PIT) enables patients with RHS to initiate high-dose antiviral medication at their own discretion as soon as prodromal symptoms appear. While famciclovir-based PIT offers the convenience of a single-day treatment and has shown efficacy comparable to low-dose, long-term regimens such as 5-day treatment, no reports have evaluated its impact on the annual recurrence rate. To investigate this further, we conducted a single-center, chart-based retrospective study to assess the effect of PIT on annual recurrence rate. Patients and Methods: Patients who visited a medical institution for RHS and who had their recurrence frequency recorded over the preceding year were included. Annual recurrence number, adherence, treatment efficacy, and other relevant factors were assessed through interviews and questionnaires. The effectiveness and safety of PIT were compared with conventional 5-day oral anti-herpesvirus treatment. Results: Sixty patients who were prescribed famciclovir for PIT were enrolled, of whom 43 with recurrent episodes were included in the efficacy analysis population. The mean number of recurrences during the first year of PIT was 2.8 (SD: 2.1), representing a significant reduction compared to 5.3 (SD: 2.9) during 5-day treatment (p < 0.001). Patient questionnaires indicated high adherence, treatment efficacy, and preference for PIT. Regarding safety, no increase in adverse events was observed compared to 5-day treatment. Conclusion: Famciclovir-based PIT significantly reduced the recurrence rate of RHS, demonstrated high adherence and treatment efficacy, was preferred by patients, and was well tolerated. These results support PIT as a promising therapeutic approach for management of recurrent herpes simplex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.